The present study determined whether repeated administration of the antidepressant and selective norepinephrine (NE) uptake inhibitor reboxetine resulted in an adaptive modification of the function of the NE transporters (NETs), serotonin (5-HT) transporters, or dopamine (DA) transporters. Because antidepressants may be effective tobacco smoking cessation agents and because antidepressants have recently been shown to interact with nicotinic acetylcholine receptors (nAChRs), the interaction of reboxetine with nAChRs was also evaluated. Repeated administration of reboxetine (10 mg
The efficacy of reboxetine, a well tolerated antidepressant in clinical use in Europe (Berzewdski et al., 1997; Montgomery, 1997) , has been linked to inhibition of neurotransmitter uptake, specifically at the norepinephrine (NE) transporter (NET). Reboxetine is a highly selective inhibitor of NET, relative to the serotonin transporter (SERT) and the dopamine transporter (DAT; Montgomery, 1997; Wong et al., 2000) . Like other antidepressants, reboxetine displays a characteristic delay in onset of action (Versiani et al., 1999) , due to prerequisite neural adaptations (Harkin et al., 2000; Invernizzi et al., 2001) . Adaptive changes in transporter function seem to be dependent on the specific antidepressant administered and transporter affected. For example, repeated administration of the SERT inhibitors citalopram and fluoxetine did not produce adaptive modifications of SERT function (Gobbi et al., 1997) . In contrast, repeated administration of the DAT inhibitor bupropion, but not nomifensine, resulted in up-regulation of DAT (Tella et al., 1997) . Thus, one purpose of the present study was to determine whether repeated reboxetine produced adaptive modifications in NET, SERT, or DAT function.
Many studies have correlated mood disorders with tobacco smoking (Glassman et al., 1990) . Individuals who are depressed are more likely to be smokers, dependent on nicotine, experience difficulty quitting, and have greater withdrawal symptoms (Covey, 1999) . Depression may also be a symptom of nicotine withdrawal, and depression associated with cessation occurs more frequently among smokers with a history of depression (Covey, 1999) . Recent clinical studies report that bupropion, an antidepressant that inhibits DAT and NET function, is a useful smoking cessation therapy (Hurt et al., 1997; Jorenby et al., 1999; Shiffman et al., 2000) .
The intrinsic rewarding properties of nicotine, the major alkaloid in tobacco believed to be responsible for maintenance of the smoking habit, result from activation of neuronal DA pathways (Corrigall et al., 1992) . Nicotinic acetylcholine receptors (nAChRs) are located on cell bodies and terminals of the hippocampal NE pathway (Sershen et al., 1997) and the nigrostriatal DA pathway (Wonnacott, 1997) . Nicotine has been shown to evoke [ flow from rat striatal slices (Teng et al., 1997) . The diversity of mRNA for nAChR subunits isolated in NE-and DA-containing neurons (Wada et al., 1989; Dineley-Miller and Patrick, 1992; Charpantier et al., 1998) supports the speculation that several nAChR subtypes may be responsible for nicotine-evoked NE and DA release. Furthermore, evidence has been obtained suggesting that nicotine-evoked NE release from hippocampus is the result of the stimulation of presynaptic ␣3␤4* nAChRs (Clarke and Reuben, 1996; Sershen et al., 1997; Reuben et al., 2000) , whereas at least in part, nicotine-evoked striatal DA release is via presynaptic ␣3␤2* nAChRs (Schulz and Zigmond, 1989; Grady et al., 1992; Cartier et al., 1996; Kaiser et al., 1998) . Convincing evidence suggests that nicotine-evoked 86 Rb ϩ efflux from thalamic synaptosomes is the result of stimulation of ␣4␤2* nAChRs. The rank order of potency of nAChR agonists to increase 86 Rb ϩ efflux from thalamic synaptosomes was highly correlated with that for inhibition of [ 3 H]nicotine binding to thalamic membranes (Marks et al., 1995) .
Recently, several antidepressants have been reported to act as nAChR antagonists in assays assessing receptor function. Specifically, desipramine, nisoxetine, and citalopram inhibited nicotine-evoked [ 3 H]NE overflow from rat hippocampal slices (Hennings et al., 1997 (Hennings et al., , 1999 and bupropion inhibited acetylcholine-induced currents in rat ␣3␤2, ␣4␤2, and ␣7 nAChRs expressed in Xenopus oocytes (Slemmer et al., 2000) . Also, bupropion and several other antidepressants, e.g., fluoxetine, sertraline, paroxetine, and nefazodone, were shown to inhibit carbamylcholine-evoked 86 Rb ϩ efflux from human muscle-type nAChRs (␣1␤␥␦) in TE671/RD cells, to inhibit carbamylcholine-evoked 86 Rb ϩ efflux from human autonomic nAChRs (␣3␤4␣5 Ϯ ␤2) in SH-SY5Y neuroblastoma cells, and to inhibit nicotine-evoked 86 Rb ϩ efflux from chick V274T mutant ␣7-nAChR heterologously expressed in native nAChR-null SH-EP1 epithelial cells (Fryer and Lukas, 1999a,b) . Although reboxetine has been established as a potent and selective inhibitor of NET, its interaction with nAChRs has not been investigated previously. Thus, the second purpose of the present study was to evaluate the interaction of reboxetine with native nAChRs containing ␣7, ␣4, and ␣3 subunits by determining reboxetine-induced inhibition of 3 H]DA uptake assays were performed using rat striatal synaptosomes. Striata or hippocampi from an individual rat were homogenized in 20 ml of ice-cold sucrose solution (0.32 M sucrose and 5 mM NaHCO 3 , pH 7.4) with 16 passes of a Teflon pestle homogenizer (clearance 0.003 inches). The homogenate was centrifuged (2000g, 10 min, 4°C), and the resulting supernatant was centrifuged (20,000g, 15 min, 4°C). The resulting pellet was resuspended in 2.4 ml of ice-cold assay buffer (125 mM NaCl, 5 mM KCl, 1.5 mM MgSO 4 , 1.25 mM CaCl 2 , 1.5 mM KH 2 PO 4 , 10 mM ␣-D-glucose, 25 mM HEPES, 0.1 mM EDTA, 0.1 mM pargyline, and 0.1 mM ascorbic acid, saturated with 95% O 2 /5% CO 2 , pH 7.4). The final protein concentration was 400 g/ml, as determined by protein-dye bonding using bovine serum albumin as a standard (Bradford, 1976) . Assays were performed in duplicate in a total volume of 500 l. Aliquot parts of synaptosomal suspension (50 l) were added to tubes containing 350 l of buffer and 50 l of one of nine concentrations of drug (reboxetine, desipramine, fluoxetine, or GBR-12909) followed by 50 l of . Accumulation proceeded for 10 min at 34°C. Accumulation was terminated by addition of 3 ml of ice-cold buffer containing catechol (1 mM) and rapid filtration through Whatman GF/B glass fiber filters presoaked with catechol (1 mM). Filters were washed three times with ice-cold buffer, transferred to scintillation vials, cocktail was added, and radioactivity was determined by liquid scintillation spectroscopy (model B1600 TR scintillation counter; Packard Instrument Company, Inc., Downer's Grove, IL).
To determine the effect of repeated reboxetine administration on [ 3 H]neurotransmitter uptake, groups of rats were injected (i.p.) twice daily (9:00 AM and 4:00 PM) with reboxetine (10 mg/kg) or 0.9% (w/v) saline vehicle for 14 days. One day after the last injection of reboxetine or saline, inhibition of (Davies et al., 1999) and [ 3 H]cytisine to probe the ␣4* nAChR (Pabreza et al., 1990 ). Binding of [ 3 H]epibatidine in the presence of cytisine (30 nM) was used to probe the ␣3* nAChR subtype (Xiao et al., 1998) . Rat whole brain, minus cerebellum, was dissected quickly, weighed, and homogenized in 9 vol/g wet weight of ice-cold 0.32 M sucrose with 10 passes of a rotating Teflon pestle homogenizer (clearance 0.003 inches; setting 50, 099CK4; Glas-Col, Terre Haute, IN). The homogenate was centrifuged (1000g, 10 min, 4°C). The resulting supernatant was centrifuged (20,000g, 20 min, 4°C) . The pellet was resuspended to a final protein concentration of 1 to 8 mg/ml. The homogenate (5 ml) was frozen at Ϫ80°C until use in the binding assay. On the day of assay, aliquot parts of membrane suspension were thawed at room temperature and diluted with 4.16 3 H]NE was determined using modifications of a previously published method (Dwoskin and Zahniser, 1986) . Coronal striatal or hippocampal slices (500 m; 6 -8 mg from striatum; 3-4 mg from hippocampus) were incubated in Krebs' buffer (118 mM NaCl, 4.7 mM KCl, 1.2 mM MgCl 2 , 1.0 mM NaH 2 PO 4 , 1.3 mM CaCl 2 , 11.1 mM ␣-D-glucose, 25 mM NaHCO 3 , 0.11 mM ascorbic acid, and 4.0 M EDTA, saturated with 95% O 2 /5% CO 2 , pH 7.4) in a metabolic shaker at 34°C for 30 min. Slices were incubated in fresh buffer containing
]NE (6 -8 slices/3 ml) for an additional 30 min. After rinsing, each slice was transferred to a glass superfusion chamber maintained at 34°C and superfused at 1 ml/min with oxygenated Krebs' buffer containing pargyline (10 M) and either nomifensine (10 M) in [ 3 H]DA release experiments or desipramine (10 M) in [ 3 H]NE release experiments to inhibit metabolism by monoamine oxidase and to inhibit uptake into the respective presynaptic terminals, ensuring that 3 H overflow represented primarily the parent 3 H-neurotransmitter rather than metabolites. After 60 min of superfusion, three 5-min samples (5 ml/sample) were collected to determine basal 3 H outflow. After collection of the third basal sample, slices from an individual rat were superfused for 30 min in the absence or presence of six to seven concentrations of reboxetine (1 nM-100 M), which remained in the buffer until the end of the experiment. Intrinsic activity (i.e., the ability of reboxetine to evoke 3 H overflow) was assessed during the 30-min period of superfusion. The complete concentration response for reboxetine in the [ 3 H]NE release assay was determined in one series of experiments. However, two series of experiments were performed to obtain the complete concentration response in the [ 3 H]DA release assay; the first series determined the effect of 1 nM to 10 M, and the second series determined the effect of 10 nM to 100 M. Subsequently, nicotine (10 M) was added to the buffer containing reboxetine, and superfusion continued for an additional 60 min. The ability of reboxetine to inhibit nicotine-evoked 3 H overflow was determined during the latter 60-min period of superfusion. Each striatal slice was exposed to only one concentration of reboxetine. Each experiment was replicated a minimum of six times. A repeated measures design was used, such that the concentration effect of reboxetine was determined using brain slices from a single rat, and a minimum of six rats. At the end of the experiment, each slice was solubilized with TS-2. The pH and volume of the solubilized tissue samples were adjusted to those of the superfusate samples. Radioactivity in the superfusate and tissue was determined by liquid scintillation spectroscopy (model B1600 TR scintillation counter; Packard Instrument Company, Inc.).
To determine the mechanism of the reboxetine-induced inhibition of nicotine-evoked [ 3 H]NE overflow, a Schild analysis was performed in which hippocampal slices were superfused in the absence or presence of a single concentration of reboxetine (10 nM, 100 nM, or 1 M), and the concentration effect for nicotine was determined. These experiments were performed as described above, except that slices from an individual rat were superfused for 30 min in the absence or presence of a single concentration of reboxetine (10 nM-1 M), and subsequently, one of six concentrations of nicotine (1 nM-100 M) was added to the buffer containing reboxetine. Superfusion continued for an additional 60 min. Each slice from a single animal was exposed to only one concentration of reboxetine and only one concentration of nicotine. These experiments also used a repeated measures design, such that the concentration effect for nicotine was determined in both the absence and presence of reboxetine using hippocampal tissue from a single rat, and a minimum of six rats for each reboxetine concentration. Additionally, one slice in each experiment was superfused in the absence of reboxetine and nicotine, constituting the buffer control condition. Slices and superfusate were processed as described previously.
Fractional release for each superfusate sample was calculated by dividing the tritium collected in each sample by the total tritium present in the tissue at the time of sample collection. Fractional release was expressed as a percentage of total tritium in the tissue at the time of sample collection. Basal 3 H outflow was calculated from the average of the tritium collected in the three 5-min samples just before the addition of reboxetine. Reboxetine-and nicotine-evoked 3 H overflow was calculated by summing the increases in collected tritium that resulted from exposure to drug and subtracting the basal outflow.
86 Rb ؉ Efflux Assay. The effects of reboxetine on 86 Rb ϩ efflux were determined using previously published methods (Miller et al., 2000) . Thalamus was homogenized and centrifuged (1000g, 10 min, 4°C). The supernatant fraction was centrifuged (12,000g, 20 min, 4°C) to obtain the synaptosomal fraction. Synaptosomes were incubated for 30 min in 35 l of buffer (140 mM NaCl, 1.5 mM KCl, 2.0 mM CaCl 2 , 1.0 mM MgSO 4 , and 20 mM ␣-D-glucose, pH 7.5) containing 4 Ci of 86 Rb ϩ . 86 Rb ϩ uptake was terminated by filtration of the synaptosomes onto glass fiber filters (6 mm, type A/E; Gelman Instrument Co., Ann Arbor, MI) under gentle vacuum (0.2 atm), followed by three washes with buffer (0.5 ml each). Subsequently, each filter with 86 Rb ϩ -loaded synaptosomes (39 Ϯ 4.8 g of protein/l) was placed on a 13-mm glass fiber filter (type A/E) mounted on a polypropylene platform. 86 Rb ϩ efflux assay buffer (125 mM NaCl, 5 mM CsCl, 1.5 mM KCl, 2 mM CaCl 2 , 1 mM MgSO 4 , 25 mM HEPES, 20 mM ␣-D-glucose, 0.1 M TTX, and 1.0 g/l bovine serum albumin, pH 7.5) was superfused at a rate of 2.5 ml/min. TTX and CsCl were included in the assay buffer to block voltage-gated Na ϩ and K ϩ channels, respectively, and to reduce the rate of basal 86 Rb ϩ efflux. The ability of reboxetine (1 nM-100 M) to inhibit 86 Rb ϩ efflux evoked by 1 M nicotine was determined. In previous experiments, this concentration of nicotine was the lowest concentration that produced maximal 86 Rb ϩ efflux (Miller et al., 2000) . After 8 min of superfusion, basal samples (sample/18 s) were collected for 2 min. Subsequently, synaptosomes were superfused for 3 min in the absence or presence of one of six concentrations (1 nM-100 M) of reboxetine. Then, nicotine (1 M) was added to buffer, and superfusion was continued for an additional 3 min, followed by superfusion for 3 min with buffer in the absence of either drug. Each aliquot part of thalamic synaptosomes was exposed to only one concentration of reboxetine. In each experiment, one synaptosomal aliquot part was also exposed to nicotine (1 M) in the absence of reboxetine, and one synaptosomal aliquot part was superfused in the absence of either drug to determine basal 86 Rb ϩ efflux during the course of the experiment. Samples were analyzed by liquid scintillation spectroscopy (model B1600 TR scintillation counter; Packard Instrument Company, Inc.). To determine the basal rate of 86 Rb ϩ efflux, an exponential decay curve was used to fit the data points proceeding and Data Analysis. For the 3 H neurotransmitter uptake assays, IC 50 values for each individual concentration-response curve were generated using nonlinear regression and a sigmoidal curve fit (GraphPad Prism, version 3.0; GraphPad Software, San Diego, CA). For the 3 H neurotransmitter uptake assays, comparisons of IC 50 values for reboxetine with desipramine, fluoxetine, or GBR-12909 were analyzed by independent group t tests. To assess the effect of repeated reboxetine treatment on inhibition of 3 H neurotransmitter uptake, twoway analysis of variance (ANOVA) was performed on the IC 50 values with repeated drug treatment (reboxetine or saline) and inhibitor (reboxetine versus desipramine, fluoxetine, or GBR-12909) as between-group factors (SPSS version 9.0; SSPS, Inc. (Table 3) . A significant main effect of reboxetine concentration was found [F (6,30) ϭ 10.67, p Ͻ 0.001], and post hoc tests revealed greater 3 H overflow after superfusion with 100 M reboxetine compared with control (0 M) or compared with lower concentrations (1 nM-10 M) of reboxetine. Furthermore, 3 H overflow from slices superfused with 1 nM to 10 M reboxetine was not different from control ( Table 3 ), indicating that these concentrations of reboxetine produced no intrinsic activity.
In a concentration-dependent manner, reboxetine inhibited nicotine (10 M)-evoked 3 H overflow from hippocampal slices preloaded with [ 3 H]NE (Fig. 2 ). An IC 50 value of 7.3 nM was obtained. Because 100 M reboxetine intrinsically evoked 3 H overflow, data from slices superfused in the presence of this concentration of reboxetine were not included in the analysis of the inhibition of the effect of nicotine. A significant main effect of reboxetine concentration was found [F (5,20) ϭ 5.19, p Ͻ 0.01], and post hoc tests revealed that 0.1 to 10 M reboxetine significantly inhibited nicotine-evoked 3 H overflow. Evaluation of the time course (Fig. 2, inset) revealed that reboxetine (10 nM-1 M) did not increase fractional [
3 H]NE release compared with fractional release from control slices, which were not exposed to reboxetine. Addition of nicotine to the buffer resulted in an immediate increase in fractional release, which returned to basal levels by the end of the superfusion period. The time course also illustrates the concentration-dependent inhibition produced by reboxetine, such that 1 M reboxetine completely inhibited the stimulation produced by this concentration of nicotine.
To determine the mechanism of reboxetine-induced inhibition of the effect of nicotine, the concentration response for nicotine-evoked (10 nM-1 M) 3 H overflow from [ 3 H]NEpreloaded hippocampal slices was determined in the absence and presence of 10 nM, 100 nM, or 1 M reboxetine (Fig. 3) . Data from this Schild analysis were analyzed via repeated measures ANOVA, which revealed a significant three-way interaction of nicotine concentration, the absence or presence of reboxetine, and reboxetine concentration [F (12,84) (Table 5) . Thus, this high concentration was not included in the analysis of reboxetine-induced inhibition of nicotineevoked 86 Rb ϩ efflux (Fig. 4) (Montgomery, 1997; Wong et al., 2000) . The current results, demonstrating that repeated injection of reboxetine does not alter its potency or selectivity to inhibit [ 3 H]NE uptake, suggest that reboxetine does not produce adaptive modifications of NET, SERT, or DAT function under Rats were injected twice daily for 14 days with reboxetine (10 mg/kg) or saline, and 3 H neurotransmitter uptake was assessed 24 h after the last injection. the current experimental conditions. Furthermore, tolerance did not develop to the reboxetine-induced inhibition of NET after repeated reboxetine administration. The same reboxetine injection regimen (10 mg/kg/day i.p., twice daily for 14 days) used in the present 3 H neurotransmitter uptake study was previously demonstrated to produce characteristic neural adaptive changes, e.g., down-regulation of ␤-adrenergic receptors (Harkin et al., 2000) , indicating that this reboxetine injection regimen was sufficient to induce neural adaptation. Because reboxetine requires 2 to 3 weeks of treatment before its antidepressant effects are ob- 3 H]NE. The superfusion buffer contained pargyline (10 M) and desipramine (10 M) from the start of the experiment. The concentration response for nicotine (10 nM-1 M) was determined in the absence and presence of 10 nM, 100 nM, or 1 M reboxetine. Reboxetine was included in the superfusion buffer for 30 min before the addition of nicotine to the buffer, and superfusion continued for an additional 60 min. Data from these three series of experiments are presented as the mean (ϮS.E.M.) of total 3 H overflow during the 60-min period of exposure to nicotine in the absence or presence of reboxetine. Because no significant differences [F (2,15) ϭ 0.17, p ϭ 0.85] were found among the control groups (i.e., the concentration response for nicotine in the absence of reboxetine) for the three series of experiments, these data were collapsed for graphical presentation. ૺ, p Ͻ 0.05, different from control (0 M reboxetine) across the corresponding nicotine concentration (n ϭ 6 rats/group).
served, direct inhibition of NET, which occurs immediately upon reboxetine treatment, cannot account entirely for its clinical efficacy. Rather, the neural adaptation must be, at least in part, responsible for the antidepressant effect of reboxetine. One possible neural adaptation may be a change in the surface expression of NET; however, an alteration in inhibition of [ 3 H]NE uptake in the current study was not observed. Thus, the present results taken together with previous findings of Harkin et al. (2000) suggest that continued inhibition of NET by reboxetine may be necessary for the neural adaptation to be manifest.
Studies have demonstrated that the antidepressant bupropion has efficacy for smoking cessation and ameliorates some nicotine withdrawal symptoms (Hurt et al., 1997; Jorenby et al., 1999; Shiffman et al., 2000) . Recently, bupropion and other antidepressants were reported to be antagonists of nAChRs (Hennings et al., 1997 (Hennings et al., , 1999 Fryer and Lukas, 1999a,b; Slemmer et al., 2000) . Bupropion inhibited rat ␣3␤2, ␣4␤2, and ␣7 nAChRs expressed in Xenopus oocytes (Slemmer et al., 2000) . Bupropion, fluoxetine, sertraline, paroxetine, and nefazodone inhibited the ␣1␤␥␦ subtype expressed in TE671/RD cells, the ␣3␤4␣5 Ϯ ␤2 subtype expressed in SH-SY5Y neuroblastoma cells, and the chick V274T mutant ␣7 subtype expressed in SH-EP1 epithelial cells (Fryer and Lukas, 1999a,b) . Desipramine, nisoxetine, and citalopram inhibited nicotine-evoked [ 3 H]NE overflow from rat hippocampal slices (Hennings et al., 1997 (Hennings et al., , 1999 , suggesting an interaction with the ␣3␤4* nAChR subtype. Based on these findings, it seems that different antidepressants may have different inhibitory profiles across the diversity of nAChR subtypes. Importantly, the specific nAChR subtype(s) inhibited may impart the pharmacological properties necessary for the inhibition of the reinforcing effect of nicotine. Thus, selected antidepressants may prove efficacious as smoking cessation pharmacotherapies, in part depending on their pharmacological profile as inhibitors of specific nAChR subtypes.
The present study provides an initial profile for the functional antagonism produced by reboxetine at several nAChR subtypes. Reboxetine potently inhibited (IC 50 value ϭ 7.3 nM) nicotine-evoked [ 3 H]NE overflow from superfused hippocampal slices, suggesting antagonism at the ␣3␤4* subtype. Furthermore, the reboxetine-induced inhibition was not surmounted by increasing concentrations of nicotine, indicative of a noncompetitive mechanism of action. It is notable that reboxetine inhibited the function of this nAChR subtype within the same concentration range that it inhibited NET function. Inclusion of desipramine in the superfusion buffer in the [ 3 H]NE release experiments eliminated the contribution of NET function to the observed effect of reboxetine to inhibit nicotine-evoked [ 3 H]NE release. The functional elimination of NET provided the necessary conditions to focus on the contribution of nAChR function to the observed effect of reboxetine. Thus, the present observation that reboxetine potently inhibited nicotine-evoked [ 3 H]NE release in the presence of desipramine strongly suggests the involvement of the ␣3␤4* nAChR. In agreement, other investigators have reported that IC 50 values for inhibition of nicotine-evoked [ 3 H]NE overflow from rat hippocampal slices are not correlated with K i values for inhibition of NET function (Hennings et al., 1999) . Thus, both the current studies and the work of others suggest that there is no relationship between antidepressant-induced inhibition of NET function and antidepressant-induced inhibition of the effect of nicotine to release NE from its presynaptic terminal in hippocampus.
Furthermore, the present results suggest that reboxetine selectively inhibits the ␣3␤4* nAChR subtype because reboxetine failed to inhibit nicotine-evoked [ 3 H]DA release from superfused rat striatal slices in the presence of nomifensine, indicating a lack of interaction with the ␣3␤2* subtype. Ad- 86 Rb ϩ efflux because desipramine was not included in the superfusion buffer at concentrations maximally inhibiting NET function. However, the concentration required to for inhibition of ␣4␤2* function was 100-fold greater than that which inhibits NET function, mitigating against the role of NET in this effect of reboxetine. Furthermore, the present results obtained using native receptors are consistent with previous results demonstrating that antidepressants noncompetitively inhibit ␣4␤2 nAChRs expressed in Xenopus oocytes in the absence of NET coexpression (Slemmer et al., 2000) .
Pharmacological interventions as smoking cessation agents are restricted in number. Currently, the noncompetitive nAChR antagonist mecamylamine, various forms of nicotine replacement therapy, and the nonselective DA/NE transport inhibitor and nAChR antagonist bupropion have been reported to show limited efficacy. Recent studies demonstrate that reboxetine inhibits nicotine self-administration in rats and that tolerance does not develop to the inhibitory properties of reboxetine after repeated administration (A. S. Rauhut, S. N. Mullins, L. P. Dwoskin, and M. T. Bardo, submitted for publication). The latter results suggest that reboxetine may be a good candidate for the treatment of nicotine dependence and may have utility as a smoking cessation agent. Furthermore, the present study suggests that the ␣3␤4* nAChR may be a novel target for therapeutic intervention in smoking cessation, and that the noradrenergic system may play a more important role than previously appreciated in nicotine-induced reward. Thus, given the concordance of smoking behavior and dysphoric mood disorders, reboxetine may provide an alternative effective treatment for tobacco smoking cessation.
